Report Highlights

China Veterinary CT Scanner Market Overview

The veterinary CT scanner market in China has undergone a structural transformation over the past decade, shifting from an almost exclusively imported-equipment base to a hybrid market where domestically manufactured Class III medical devices now account for a growing share of new installations. Market size reached USD 187.4 million in 2024, supported by a national pet population exceeding 130 million companion animals and a licensed veterinary hospital network that surpassed 19,000 facilities following the 2023 revision of the Veterinary Law of the People's Republic of China. Government policy has been the dominant force in shaping market structure, with the Ministry of Agriculture and Rural Affairs (MARA) and the National Medical Products Administration (NMPA) jointly setting the equipment registration, facility licensing, and import approval frameworks that determine which products can legally operate in Chinese veterinary settings.

Private sector investment has led physical infrastructure expansion, particularly among corporate veterinary chains such as New Ruipeng Pet Healthcare Group and Guizhou-based Yierkang, which have accelerated CT suite installations to differentiate premium service tiers. However, pricing, product registration pathways, and facility-level equipment mandates remain government-controlled levers. The NMPA's requirement that all veterinary CT scanners intended for clinical use must obtain Class III medical device registration before sale — a process averaging 18 to 24 months for foreign applicants — means that policy gatekeeping continues to define which competitors can access Chinese veterinary institutions and on what timeline.

Policy-Driven Growth in China's Veterinary CT Scanner Market

Three specific policy mechanisms are directly driving demand growth in veterinary CT scanners across China. First, the revised Veterinary Law enacted in May 2023 introduced mandatory diagnostic capability standards for Class II and Class III veterinary hospitals, requiring designated imaging equipment including advanced cross-sectional modalities for the first time. This mandate created an immediate addressable upgrade market estimated at over 2,400 hospitals seeking compliance by the MARA-set deadline of December 2025. Second, the Ministry of Finance's 2023 Agricultural Machinery Purchase Subsidy Programme was extended to include veterinary diagnostic imaging equipment for the first time, offering subsidies of up to RMB 150,000 per unit for domestically manufactured veterinary CT systems procured by county-level agricultural veterinary stations, directly stimulating rural and semi-urban demand channels that had previously been economically inaccessible.

Third, the State Council's 14th Five-Year Plan for the Pet Economy, circulated as Guofa [2022] No. 18, set explicit targets for upgrading veterinary diagnostic infrastructure in 30 designated "pet economy pilot cities" by 2025. Municipal governments in Chengdu, Guangzhou, and Hangzhou have disbursed ring-fenced grants of RMB 500,000 to RMB 2 million per qualifying veterinary facility to fund imaging suite construction, with CT scanners listed as priority equipment. Each mechanism translates directly into procurement events: the hospital licensing mandate creates compliance-driven purchasing, the agricultural subsidy creates rural channel demand, and the pilot city grants create capital-funded urban hospital expansion spending.

Regulatory Barriers and Compliance Costs

The primary regulatory barrier for foreign veterinary CT scanner manufacturers is the NMPA Class III medical device registration process, administered under the Medical Device Supervision and Administration Regulations (State Council Order No. 739). Foreign applicants must submit full technical dossiers, clinical evaluation data from Chinese veterinary sites, and localised software documentation. The average approval timeline for a first-in-class veterinary CT submission is 22 months, compared to 10 to 12 months for domestic applicants benefiting from the NMPA's streamlined "innovative medical device" green channel under the 2021 Special Approval Procedures for Innovative Medical Devices. Registration fees, mandatory local clinical trials, and in-country authorised representative requirements add between RMB 1.2 million and RMB 3.5 million in compliance costs per product line before a single unit is sold.

A second significant barrier is the local content and procurement preference policy embedded in the Government Procurement Law of the People's Republic of China, which directs public veterinary institutions — including MARA-affiliated animal disease control centres and university veterinary teaching hospitals — to preference domestically registered and manufactured equipment when the price differential is within 20%. Administered by the Ministry of Finance through its Government Procurement Information System, this policy effectively excludes premium-priced imported CT systems from a substantial portion of institutional procurement tenders. Additionally, Customs Tariff Commission Announcement No. 6 (2023) maintained a 10% import duty on veterinary imaging equipment classified under HS code 9022.12, adding direct cost pressure for foreign OEMs without local manufacturing partnerships.

Policy-Created Opportunities in China's Veterinary Imaging Sector

The MARA's National Animal Disease Prevention and Control Medium and Long-Term Plan (2023–2030) creates a structured procurement opportunity for veterinary CT systems at county-level animal disease prevention and control centres across 31 provinces. The plan allocates RMB 8.6 billion nationally for diagnostic infrastructure upgrades, with provincial MARA branches required to submit annual equipment procurement lists to the central treasury. Veterinary CT scanners capable of large-animal scanning — specifically equine and bovine applications — are explicitly listed as eligible equipment categories. This creates a government-funded demand pipeline that is largely insulated from commercial market cycles and accessible primarily through registered domestic distributors holding MARA supplier qualification certificates.

A second significant opportunity arises from the NMPA's 2024 announcement of a dedicated veterinary medical device sub-classification framework, expected to take effect in 2026. This framework will create a standalone regulatory pathway for veterinary-specific CT systems, separating them from the human medical device track for the first time. Companies that engage the NMPA's Centre for Medical Device Evaluation during the 2025 consultation period and pre-submit under the new framework gain first-mover registration advantage estimated at 12 to 18 months ahead of competitors who wait for finalised guidance. For international OEMs with strong R&D portfolios, this regulatory window represents the clearest entry-timing opportunity in a decade.

Market at a Glance

Leading Market Participants

• Siemens Healthineers
• Canon Medical Systems
• GE HealthCare
• Neusoft Medical Systems
• Shenzhen Anke High-Tech
• United Imaging Healthcare
• Philips Healthcare
• Mindray Medical International
• SternMed
• Epica Medical Innovations

Regulatory and Policy Environment

The primary legislative instrument governing veterinary CT scanners in China is the Medical Device Supervision and Administration Regulations (State Council Order No. 739, revised 2021), supplemented by the NMPA's Classification Catalogue of Medical Devices, which lists veterinary CT systems under Class III — the highest risk and most stringent regulatory tier. The NMPA's Centre for Medical Device Evaluation administers pre-market review, while post-market surveillance is enforced through the Adverse Event Monitoring System under NMPA Order No. 1 (2021). Key compliance requirements include mandatory unique device identification (UDI) tagging under the National Medical Device UDI Database, annual quality management system audits under YY/T 0287 (equivalent to ISO 13485), and mandatory software lifecycle documentation for AI-assisted imaging features under the NMPA's 2022 Guiding Principles for AI Medical Devices. Compared to regional peers, China's framework is more prescriptive than Japan's PMDA veterinary device pathway and significantly more burdensome than South Korea's MFDS process, particularly for foreign applicants lacking local manufacturing.

Upcoming regulatory changes expected by 2026 include the implementation of the standalone veterinary medical device sub-classification framework announced in NMPA's 2024 work plan, which will introduce veterinary-specific technical standards replacing the current human-device-adapted requirements. The MARA is also expected to gazette updated Veterinary Hospital Classification Standards by mid-2025, formally mandating CT imaging capability for all facilities seeking Class III veterinary hospital status — a designation currently held by fewer than 600 hospitals but targeted at 1,500 by 2030 under MARA's veterinary services development roadmap. These overlapping regulatory triggers will compress procurement decision cycles and elevate compliance-based purchasing as the dominant demand driver through the forecast period.

Long-Term Policy Outlook for China's Veterinary CT Scanner Market

By 2032, the regulatory architecture governing veterinary CT scanners in China will be substantially more developed than it is today, creating both higher barriers to entry and more predictable demand signals. The NMPA's standalone veterinary device pathway, once fully operational, will enable faster registration cycles for purpose-built veterinary CT platforms — reducing approval timelines for compliant domestic manufacturers to as little as 8 months. Simultaneously, the MARA's 2023–2030 infrastructure plan will have progressed through its mid-term review by 2027, likely triggering a second procurement wave targeting prefecture-level veterinary diagnostic centres. Manufacturers that have achieved NMPA veterinary-category registration before 2026 will be positioned to capture sole-source contracts during this second wave, given the preference policies embedded in the Government Procurement Law.

The broader policy environment through 2032 will also be shaped by China's ambitions in veterinary biologics and food safety surveillance, both of which increase demand for advanced diagnostic imaging at the intersection of companion animal healthcare and livestock disease management. The 14th and expected 15th Five-Year Plans both identify animal health infrastructure as a national food security priority, meaning central government capital allocation to veterinary diagnostic equipment is structurally protected from fiscal consolidation. For market participants, this means the primary long-term risk is not demand erosion but rather regulatory lock-out — the consequence of failing to navigate NMPA registration, UDI compliance, and local content thresholds before the market's policy-driven procurement cycles crystallise after 2026.